Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized, Double-masked, Active-controlled, Dose-response Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension

NCT05913232 is registered in ClinicalTrials.gov with D. Western Therapeutics Institute, Inc. as lead sponsor.

NCT NCT05913232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05913232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized, Double-masked, Active-controlled, Dose-response Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension
Lead sponsor
D. Western Therapeutics Institute, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2023
Completion date
August 29, 2024
Enrollment
201 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma open-angle primary, ocular hypertension